Compare THS & CAPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | THS | CAPR |
|---|---|---|
| Founded | 2021 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Packaged Foods | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.4B |
| IPO Year | N/A | N/A |
| Metric | THS | CAPR |
|---|---|---|
| Price | $24.60 | $24.82 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 7 | 8 |
| Target Price | $24.67 | ★ $41.38 |
| AVG Volume (30 Days) | 658.3K | ★ 1.2M |
| Earning Date | 02-13-2026 | 03-18-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $3,336,000,000.00 | $11,130,509.00 |
| Revenue This Year | $1.43 | N/A |
| Revenue Next Year | $0.65 | $16,329.74 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $15.85 | $4.30 |
| 52 Week High | $40.77 | $40.37 |
| Indicator | THS | CAPR |
|---|---|---|
| Relative Strength Index (RSI) | 72.17 | 54.85 |
| Support Level | $24.43 | $21.75 |
| Resistance Level | $24.73 | $23.86 |
| Average True Range (ATR) | 0.19 | 1.29 |
| MACD | 0.00 | -0.28 |
| Stochastic Oscillator | 75.14 | 80.39 |
TreeHouse Foods is the largest pure-play private-label manufacturer in the US. Much larger in the past following the 2016 acquisition of Ralcorp, Conagra's former private-label business, the company has since divested several businesses to focus on high-growth categories. At present, the company produces and sells snacks (crackers, pretzels, cookies, and so on), beverages (such as nondairy creamer, coffee, tea, and broth), and a select number of grocery products (pickles, refrigerated dough, hot cereal, cheese, and pudding). Its most important sales channel is through retail grocery stores that sell its products under their own brands, with co-manufacturing and food away from home as much smaller channels of distribution for its fare.
Capricor Therapeutics Inc is a clinical-stage biotechnology company focused on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (DMD), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with high unmet medical needs. The company's product pipeline includes CAP-1002, deramiocel an allogeneic cardiac-derived cell therapy. Deramiocel is currently advancing through Phase 3 clinical development for the treatment of Duchenne muscular dystrophy. Through its proprietary StealthXTM platform, the group uses its exosome technology to conduct preclinical research focused on vaccinology, delivering oligonucleotides, proteins, and small molecules to treat.